Nuclear Medicine/Radiopharmaceuticals - Market Insights, Competitive Landscape, and Market Forecast - 2030

Nuclear Medicine/Radiopharmaceuticals Market By Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-123, Xenon-133, And Others}, And Positron Emission Tomography (Pet) {Flourine-18, Carbon-11, Gallium-68, And Others}], Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, And Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, And Others}, And Brachytherapy]), By Application (Cardiology, Neurology, Oncology, And Others), By End-User (Hospitals, Diagnostic Centers, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of chornic diseases such as cardiovascular, cancers, and others and the increasing research & developmental activites concerning to the radiopharmaceuticals across the globe

The global nuclear medicine/radiopharmaceuticals market was valued at USD 7,203.62 million in 2022 and is estimated to grow at a CAGR of 9.67% during the forecast period from 2024 to 2030 to reach USD 12,495 million by 2030. The nuclear medicine/radiopharmaceuticals market is observing a substantial market growth due to the growing prevalence of cancer, cardiovascular, and other chronic diseases owing to the inactive routine. Further, the increasing number of geriatric population prone to chronic diseases, increasing demand for image guided procedures and diagnostics across the world, and presence of a robust products in pipeline will propel the demand of nuclear medicine during the forecast period. Additionally, favorable government initiatives to improve access to nuclear medicine and research collaborations and partnerships will also aid in driving the market of nuclear medicine. Likewise, the increasing research & developmental activities along with the surging nuclear medicine approvals and radiopharmaceutical diagnosis device launches, presence of key players in the market, and other factors will create a requisite for the nuclear medicine/radiopharmaceuticals in the market. Therefore, the market for nuclear medicine/radiopharmaceuticals is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Nuclear Medicine/Radiopharmaceuticals Market Dynamics:

One of the key aspect for driving the nuclear medicine/radiopharmaceuticals market is the increasing prevalence of cancer, cardiovascular diseases, among others, across the world, owing to various factors such as genetics, age, obesity, and unhealthy lifestyles.

For instance, according to Globocan 2022, there were 19.3 million new cancer cases worldwide in 2020, with the number expected to rise to 30.2 million cases by 2040. The nuclear medicines are used in cancer treatment, such as radiotherapy, leading to an increased demand for nuclear medicine. Also, the nuclear medicine can even be used in the diagnosis of many neuroendocrine tumors, prostate cancer, and other oncologic malignancies.

Moreover, as per the World Health Organization (WHO) 2022, an estimated 17.9 million people died from cardiovascular disorders (CVDs), in 2019, globally. The single photon emission computerized tomography (SPECT) finds applications in cardiology, which provides metabolic and functional information about the heart. Thus, the mortality rate from CVD can be reduced by doing proper diagnosis using nuclear medicine at an apt time.

Additionally, the launch of nuclear medicine centers providing accessibility to nuclear medicine treatments across the world is further expected to boost the market of nuclear medicine. For instance, in May 2022, Penang Adventist Hospital (PAH), located in Pulau Pinang, Malaysia, launched a full-fledged private nuclear medicine center in northern Malaysia. The new facility offers diagnostic and treatment procedures for specific conditions and diseases such as hyperthyroidism, thyroid cancer, lymphomas, and bone pain caused by different types of cancer.

Further, the increasing technological advancements pertaining to the diagnosis and treatment of diseases, and rising approval of new nuclear medicine based devices aid in addressing patients treatment needs will drive the market in the forthcoming years. For instance, in September 2022, GE Healthcare announced the launch of a novel nuclear medicine scanner with a new automated workflow feature that offers an exceptional view of cardiac anatomy and pathology to help physicians to decide the right treatment for a patient.

Therefore, the factors stated above collectively will drive the overall nuclear medicine or radiopharmaceuticals market throughout the forecast period from 2024-2030.

However high cost of nuclear medicine and equipment involved in the procedure, the stringent regulatory approval process, and others may prove to be challenging factors for nuclear medicine/radiopharmaceuticals market growth.

The nuclear medicine/radiopharmaceuticals market was negatively impacted during the period of COVID- 19 pandemic as the outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitalization and diagnostic procedures. This resulted in the reduced number of routine clinical examinations and diagnosis procedures. However, vaccine development of COVID-19 has initiated the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of regular healthcare services such as outpatients visits for diagnosis and treatment purpose, thereby bringing the demand for products on track in the nuclear medicine or radiopharmaceuticals market.

Nuclear Medicine/Radiopharmaceuticals Market Segment Analysis:

Nuclear Medicine/Radiopharmaceuticals Market by Product Type (Diagnostic Products [Single Photon Emission Computed Tomography (SPECT) {Technetium-99m, Iodine-123, Xenon-133, and Others}, and Positron Emission Tomography (PET) {Flourine-18, Carbon-11, Gallium-68, and Others}], Therapeutic Products [Alpha Emitters {Astatine-211, Actinium-225, Lead-212, and Others}, Beta Emitters {Lutetium-177, Iodine-131, Yttrium-90, and Others}, and Brachytherapy]), Application (Cardiology, Neurology, Oncology, And Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the nuclear medicine or radiopharmaceuticals market, the Iodine-125 segment is expected to have a significant revenue share in the year 2023. This is due to the various advantages and applications that are associated with the segment.

Iodine-125 seed implantation can be used in radiation therapy as brachytherapy to treat a number of types of tumors, including prostate cancer, uveal melanomas, brain tumors, rectal carcinoma, advanced pancreatic cancer, and non-small cell lung cancer.

Additionally, the Iodine-125 can also be used in the treatment of gastric cancer, colorectal cancer, liver cancer, gynecological tumor, urinary, nervous system tumor, and others.

Moreover, the Iodine-125 can be used in scanning/imaging of the thyroid. Also, the 125I is useful for glomerular filtration rate (GFR) testing in the diagnosis or monitoring of patients with kidney disease.

Further, in May 2022, a unique collaboration in the field of nuclear medicine has been set up between the Nuclear Research & consultancy Group (NRG) and McMaster University to advance customer service to a new level. Together, they will provide the world with the highest quality radioiodine (iodine-125), used for the treatment of prostate and other various types of cancers, at the highest level of reliability.

Therefore, owing to the above-mentioned factors, the demand of the Iodine-125 upsurges, thereby the category is expected to witness a considerable growth eventually contributing to the overall growth of the global nuclear medicine or radiopharmaceuticals market during the forecast period.

North America is expected to dominate the overall Nuclear Medicine/Radiopharmaceuticals Market:

Among all the regions, North America is expected to dominate the global nuclear medicine or radiopharmaceuticals market in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the growing incidence of cancer, cardiovascular disorders, and others in the region due to the high consumption of processed food and lifestyle changes. Further, the presence of key domicile players in the region, rising burden of geriatric population prone to chronic diseases, favorable reimbursement scenario for radiopharmaceuticals in the United States, and others are among the key factors that contribute to the growth of the nuclear medicine/radiopharmaceuticals market in North America during the forecast period from 2022 - 2028.

For instance, as per the Cancer Facts & Figures 2022, it was estimated in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths, in the United States. Thus, the increasing incidence of cancers will surge the demand of nuclear medicines as they are used in the treatment of cancers.

Furthermore, several key players in the United States are taking initiatives to develop new technologies and improve radioisotope options. For example, Eckert & Ziegler Radio pharma GmbH successfully submitted an amendment to their Drug Master File (DMF) for GalliaPharm to the US Food and Drug Administration in September 2022. Gallium-68 from GalliaPharm is used to make diagnostic imaging drugs for Positron Emission Tomography (PET). With the development of higher Ge-68 activity generators and the revision of our DMF, there will be an increase in demand for Ga-68-based diagnostics in the United States.

Also, in October 2022, the U.S. FDA issued a Study May Proceed letter to Curium to begin its Phase-III trial with lutetium Lu 177 PSMA I&T, its investigational product. It is a therapeutic radiopharmaceutical that binds to the Prostate-Specific Membrane Antigen (PSMA) protein.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the nuclear medicine or radiopharmaceuticals market.

Nuclear Medicine/Radiopharmaceuticals Market Key Players:

Some of the key market players operating in the nuclear medicine/radiopharmaceuticals market includes Lantheus., Cardinal Health., GE Healthcare, Curium Pharma, Nihon Medi-Physics Co., Ltd., Novartis (Advanced Accelerator Applications), Cambridge Isotope Laboratories, Inc, Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, Necsa, IBA Radiopharma Solutions, Bayer AG, Norgine, EczacIbasI-Monrol, NorthStar Medical Radioisotopes, LLC., Eckert & Ziegler., Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, and others.

Recent Developmental Activities in the Nuclear Medicine:

In March 2022, Bracco Imaging launched Blue Earth Therapeutics to advance the development of therapeutic radiopharmaceutical technology. Blue Earth Therapeutics is building a pipeline of precision-targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer, with plans to expand into additional disease areas in oncology.

In February 2022, Applied Molecular Therapies launched 177Lu PSMATherapy, a molecularly targeted radiopharmaceutical, for treating prostate cancer.

In February 2022, Cerveau Technologies, Inc. and Nihon Medi-Physics announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F] MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.

Key Takeaways from the nuclear medicine/radiopharmaceuticals Market Report Study

• Market size analysis for current nuclear medicine/radiopharmaceuticals market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the nuclear medicine/radiopharmaceuticals market.
• Top key products/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global nuclear medicine/radiopharmaceuticals market.
• Various opportunities available for the other competitor in the nuclear medicine/radiopharmaceuticals market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current nuclear medicine/radiopharmaceuticals market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for nuclear medicine/radiopharmaceuticals market growth in the coming future?

Target Audience who can be benefited from this Nuclear Medicine/Radiopharmaceuticals Market Report Study

• Nuclear medicine/radiopharmaceuticals providers
• Research organizations and consulting companies
• Nuclear medicine/radiopharmaceuticals-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in nuclear medicine/radiopharmaceuticals
• Various end users who want to know more about the nuclear medicine/radiopharmaceuticals market and latest technological developments in the nuclear medicine/radiopharmaceuticals market.

Frequently Asked Questions for the Nuclear Medicine/Radiopharmaceuticals Market:

1. What are nuclear medicine/radiopharmaceuticals market?

The nuclear medicine is a subfield of molecular imaging that involves the use of radioactive materials or the radiopharmaceuticals to either diagnose or treat the disease. In nuclear medicine imaging, radioisotopes are detected by special cameras attached to a computer, which produces very precise images of the area of the body being examined.

2. What is the global market for nuclear medicine/radiopharmaceuticals market?

The global nuclear medicine/radiopharmaceuticals market was valued at USD 7,203.62 million in 2022 and is estimated to grow at a CAGR of 9.67% during the forecast period from 2024 to 2030 to reach USD 12,495 million by 2030.

3. What are the drivers for the global nuclear medicine/radiopharmaceuticals market?

The nuclear medicine/radiopharmaceuticals market is witnessing a positive market growth owing to the factors such as the rising prevalence of cancer, cardiovascular, and other chronic diseases owing to the sedentary and unhealthy lifestyle. Further, the increasing number of geriatric population prone to chronic diseases, increasing demand for image guided procedures and diagnostics, surging product launches and approvals, presence of key players in the market, and others will create an exigency for the nuclear medicine/radiopharmaceuticals market.

4. Who are the key players operating in the global nuclear medicine/radiopharmaceuticals market?

Some of the key market players operating in the nuclear medicine/radiopharmaceuticals market includes Lantheus., Cardinal Health., GE Healthcare, Curium Pharma, Nihon Medi-Physics Co., Ltd., Novartis (Advanced Accelerator Applications), Cambridge Isotope Laboratories, Inc, Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, Necsa, IBA Radiopharma Solutions, Bayer AG, Norgine, EczacIbasI-Monrol, NorthStar Medical Radioisotopes, LLC., Eckert & Ziegler., Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, and others.

5. Which region has the highest share for the nuclear medicine/radiopharmaceuticals market?

Among all the regions, North America is estimated to hold a significant revenue share in the global nuclear medicine/radiopharmaceuticals market. This can be ascribed to the growing incidence of cancer, cardiovascular disorders, and others due to the high consumption of processed food and lifestyle changes, rising geriatric population base in the region, and the presence of key domicile players in the region are the reasons which acts as a supportive factor for the North America nuclear medicine/radiopharmaceuticals market growth.